ArticleCell discovery2025

Inhaled bispecific single-domain antibody BM219 for mild-to-moderate COVID-19: a double-blind, randomized, placebo-controlled phase 2 trial.

Yanling Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.